Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 in BCP-ALL with MEF2D Rearrangement
NCT07854652Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ifupinostat in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Overall Response Rate at 6 weeks and Complete Measurable Residual Disease Response Rate at 6 weeks. Started Sep 2026; status: recruiting.
02
Drugs
ifupinostat
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07854652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854652.